<?xml version="1.0" encoding="iso-8859-1" ?>
<PASBIO>
    <framesest>
        <predicate lemma="recognize">
            <roleset id="recognize.01" name="" wordnet="3">
                <roles>
                    <role n="0" descr="agent&#x0A;" />
                    <role n="1" descr="thing being identified&#x0A;" />
                </roles>
                <example src="EGRAM" no="0">
                    <text>A approximately 70kD polypeptide in western blots of extraocular muscle, sternothyroid muscle, and smooth muscle has been recognized by Anti-64kD human autoantigen D1 antibodies.</text>
                    <arg n="0">Anti-64kD human autoantigen D1 antibodies</arg>
                    <arg n="1">a approximately 70kD polypeptide in western blots of extraocular muscle, sternothyroid muscle, and smooth muscle</arg>
                </example>
                <example src="EGRAM" no="1">
                    <text>A approximately 70kD polypeptide in western blots of extraocular muscle, sternothyroid muscle, and smooth muscle is recognized by Anti-64kD human autoantigen D1 antibodies.</text>
                    <arg n="0">Anti-64kD human autoantigen D1 antibodies</arg>
                    <arg n="1">a approximately 70kD polypeptide in western blots of extraocular muscle, sternothyroid muscle, and smooth muscle</arg>
                </example>
                <example src="EGRAM" no="2">
                    <text>A approximately 70kD polypeptide in western blots of extraocular muscle, sternothyroid muscle, and smooth muscle was recognized by Anti-64kD human autoantigen D1 antibodies.</text>
                    <arg n="0">Anti-64kD human autoantigen D1 antibodies</arg>
                    <arg n="1">a approximately 70kD polypeptide in western blots of extraocular muscle, sternothyroid muscle, and smooth muscle</arg>
                </example>
                <example src="EGRAM" no="3">
                    <text>A approximately 70kD polypeptide in western blots of extraocular muscle, sternothyroid muscle, and smooth muscle will be recognized by Anti-64kD human autoantigen D1 antibodies.</text>
                    <arg n="0">Anti-64kD human autoantigen D1 antibodies</arg>
                    <arg n="1">a approximately 70kD polypeptide in western blots of extraocular muscle, sternothyroid muscle, and smooth muscle</arg>
                </example>
                <example src="EGRAM" no="4">
                    <text>A monoclonal antibody which has recognized the STAT1 N-terminus was purchased from Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">A monoclonal antibody</arg>
                    <arg n="1">the STAT1 N-terminus</arg>
                </example>
                <example src="EGRAM" no="5">
                    <text>A monoclonal antibody which recognizes the STAT1 N-terminus is purchased from Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">A monoclonal antibody</arg>
                    <arg n="1">the STAT1 N-terminus</arg>
                </example>
                <example src="EGRAM" no="6">
                    <text>A number of Ags which is recognized by class I-restricted melanoma-specific T cells have recently been isolated, raising the hope that this will lead to the development of improved therapies.</text>
                    <arg n="0">class I-restricted melanoma-specific T cells</arg>
                    <arg n="1">A number of Ags</arg>
                </example>
                <example src="EGRAM" no="7">
                    <text>A number of Ags which was recognized by class I-restricted melanoma-specific T cells have recently been isolated, raising the hope that this will lead to the development of improved therapies.</text>
                    <arg n="0">class I-restricted melanoma-specific T cells</arg>
                    <arg n="1">A number of Ags</arg>
                </example>
                <example src="EGRAM" no="8">
                    <text>Affinity-purified polyclonal anti-LMP-1 antiserum recognized epitopes in the C-terminus of LMP-1 at a 1:200 dilution.</text>
                    <arg n="0">affinity-purified polyclonal anti-LMP-1 antiserum</arg>
                    <arg n="1">epitopes in the C-terminus of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="EGRAM" no="9">
                    <text>Affinity-purified polyclonal anti-LMP-1 antiserum recognizes epitopes in the C-terminus of LMP-1 at a 1:200 dilution.</text>
                    <arg n="0">affinity-purified polyclonal anti-LMP-1 antiserum</arg>
                    <arg n="1">epitopes in the C-terminus of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="EGRAM" no="10">
                    <text>Anti-64kD human autoantigen D1 antibodies recognized specifically a approximately 70kD polypeptide in western blots of extraocular muscle, sternothyroid muscle, and smooth muscle.</text>
                    <arg n="0">Anti-64kD human autoantigen D1 antibodies</arg>
                    <arg n="1">a approximately 70kD polypeptide in western blots of extraocular muscle, sternothyroid muscle, and smooth muscle</arg>
                </example>
                <example src="EGRAM" no="11">
                    <text>As a result of alternate splicing and subsequent frameshift, the reported g16 protein is 603 amino acids shorter than the NY-LU-12 product (1123 residues) at its COOH terminus and would therefore lack the epitopes that the autologous serum has recognized.</text>
                    <arg n="0">the autologous serum</arg>
                    <arg n="1">the epitopes</arg>
                </example>
                <example src="EGRAM" no="12">
                    <text>As a result of alternate splicing and subsequent frameshift, the reported g16 protein is 603 amino acids shorter than the NY-LU-12 product (1123 residues) at its COOH terminus and would therefore lack the epitopes that the autologous serum is able to recognize.</text>
                    <arg n="0">the autologous serum</arg>
                    <arg n="1">the epitopes</arg>
                </example>
                <example src="EGRAM" no="13">
                    <text>As a result of alternate splicing and subsequent frameshift, the reported g16 protein is 603 amino acids shorter than the NY-LU-12 product (1123 residues) at its COOH terminus and would therefore lack the epitopes which are recognized by the autologous serum.</text>
                    <arg n="0">the autologous serum</arg>
                    <arg n="1">the epitopes</arg>
                </example>
                <example src="EGRAM" no="14">
                    <text>As a result of alternate splicing and subsequent frameshift, the reported g16 protein is 603 amino acids shorter than the NY-LU-12 product (1123 residues) at its COOH terminus and would therefore lack the epitopes which were recognized by the autologous serum.</text>
                    <arg n="0">the autologous serum</arg>
                    <arg n="1">the epitopes</arg>
                </example>
                <example src="EGRAM" no="15">
                    <text>Blots were probed with affinity-purified polyclonal anti-LMP-1 antiserum recognizing epitopes in the C-terminus of LMP-1 at a 1:200 dilution.</text>
                    <arg n="0">affinity-purified polyclonal anti-LMP-1 antiserum</arg>
                    <arg n="1">epitopes in the C-terminus of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="EGRAM" no="16">
                    <text>Blots were probed with affinity-purified polyclonal anti-LMP-1 antiserum that can recognize epitopes in the C-terminus of LMP-1 at a 1:200 dilution.</text>
                    <arg n="0">affinity-purified polyclonal anti-LMP-1 antiserum</arg>
                    <arg n="1">epitopes in the C-terminus of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="EGRAM" no="17">
                    <text>Blots were probed with affinity-purified polyclonal anti-LMP-1 antiserum that recognized epitopes in the C-terminus of LMP-1 at a 1:200 dilution.</text>
                    <arg n="0">affinity-purified polyclonal anti-LMP-1 antiserum</arg>
                    <arg n="1">epitopes in the C-terminus of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="EGRAM" no="18">
                    <text>Class I-restricted melanoma-specific T cells recognize A number of Ags isolating, raising the hope that this will lead to the development of improved therapies.</text>
                    <arg n="0">class I-restricted melanoma-specific T cells</arg>
                    <arg n="1">A number of Ags</arg>
                </example>
                <example src="EGRAM" no="19">
                    <text>Class I-restricted melanoma-specific T cells recognized A number of Ags isolating, raising the hope that this will lead to the development of improved therapies.</text>
                    <arg n="0">class I-restricted melanoma-specific T cells</arg>
                    <arg n="1">A number of Ags</arg>
                </example>
                <example src="EGRAM" no="20">
                    <text>Epitopes in the C-terminus of LMP-1 at a 1:200 dilution are recognized by affinity-purified polyclonal anti-LMP-1 antiserum that blots were probed with.</text>
                    <arg n="0">affinity-purified polyclonal anti-LMP-1 antiserum</arg>
                    <arg n="1">epitopes in the C-terminus of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="EGRAM" no="21">
                    <text>Exactly how specific splice sites have been recognized during the processing of complex precursor messenger RNAs is not clear.</text>
                    <arg n="1">splice sites</arg>
                </example>
                <example src="EGRAM" no="22">
                    <text>Exactly how specific splice sites were recognized during the processing of complex precursor messenger RNAs is not clear.</text>
                    <arg n="1">splice sites</arg>
                </example>
                <example src="EGRAM" no="23">
                    <text>Exactly how specific splice sites will be recognized during the processing of complex precursor messenger RNAs is not clear.</text>
                    <arg n="1">splice sites</arg>
                </example>
                <example src="EGRAM" no="24">
                    <text>Footprinting assays have suggested that these regulators protect a stretch of up to 20 bp in the target promoters, and multiple alignments of binding sites for a number of regulators have shown that the proteins are able to recognize short motifs within the protected region.</text>
                    <arg n="0">the proteins</arg>
                    <arg n="1">short motifs within the protected region</arg>
                </example>
                <example src="EGRAM" no="25">
                    <text>Footprinting assays have suggested that these regulators protect a stretch of up to 20 bp in the target promoters, and multiple alignments of binding sites for a number of regulators have shown that the proteins can recognize short motifs within the protected region.</text>
                    <arg n="0">the proteins</arg>
                    <arg n="1">short motifs within the protected region</arg>
                </example>
                <example src="EGRAM" no="26">
                    <text>Footprinting assays have suggested that these regulators protect a stretch of up to 20 bp in the target promoters, and multiple alignments of binding sites for a number of regulators have shown that the proteins has recognized short motifs within the protected region.</text>
                    <arg n="0">the proteins</arg>
                    <arg n="1">short motifs within the protected region</arg>
                </example>
                <example src="EGRAM" no="27">
                    <text>Footprinting assays have suggested that these regulators protect a stretch of up to 20 bp in the target promoters, and multiple alignments of binding sites for a number of regulators have shown that the proteins recognized short motifs within the protected region.</text>
                    <arg n="0">the proteins</arg>
                    <arg n="1">short motifs within the protected region</arg>
                </example>
                <example src="EGRAM" no="28">
                    <text>Individual cell clones were analyzed for STAT1 expression by immunofluorescence where the STAT1 N-terminus are recognized by a monoclonal antibody.</text>
                    <arg n="0">a monoclonal antibody</arg>
                    <arg n="1">the STAT1 N-terminus</arg>
                </example>
                <example src="EGRAM" no="29">
                    <text>Individual cell clones were analyzed for STAT1 expression by immunofluorescence where the STAT1 N-terminus were recognized by a monoclonal antibody.</text>
                    <arg n="0">a monoclonal antibody</arg>
                    <arg n="1">the STAT1 N-terminus</arg>
                </example>
                <example src="EGRAM" no="30">
                    <text>Individual cell clones were analyzed for STAT1 expression by immunofluorescence with a monoclonal antibody which recognized the STAT1 N-terminus, and by western blotting</text>
                    <arg n="0">a monoclonal antibody</arg>
                    <arg n="1">the STAT1 N-terminus</arg>
                </example>
                <example src="EGRAM" no="31">
                    <text>Individual cell clones were analyzed for STAT1 expression by immunofluorescence with a monoclonal antibody which recognizes the STAT1 N-terminus, and by western blotting</text>
                    <arg n="0">a monoclonal antibody</arg>
                    <arg n="1">the STAT1 N-terminus</arg>
                </example>
                <example src="EGRAM" no="32">
                    <text>Most regulators belonging to the AraC/XylS family are able to recognize multiple binding sites in the regulated promoters.</text>
                    <arg n="0">Most regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple binding sites</arg>
                </example>
                <example src="EGRAM" no="33">
                    <text>Most regulators belonging to the AraC/XylS family can recognize multiple binding sites in the regulated promoters.</text>
                    <arg n="0">Most regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple binding sites</arg>
                </example>
                <example src="EGRAM" no="34">
                    <text>Most regulators belonging to the AraC/XylS family have recognized multiple binding sites in the regulated promoters.</text>
                    <arg n="0">Most regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple binding sites</arg>
                </example>
                <example src="EGRAM" no="35">
                    <text>Most regulators belonging to the AraC/XylS family recognized multiple binding sites in the regulated promoters.</text>
                    <arg n="0">Most regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple binding sites</arg>
                </example>
                <example src="EGRAM" no="36">
                    <text>Most regulators belonging to the AraC/XylS family will recognize multiple binding sites in the regulated promoters.</text>
                    <arg n="0">Most regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple binding sites</arg>
                </example>
                <example src="EGRAM" no="37">
                    <text>The C-terminus of CD40 at a 1:500 dilution is recognized by rabbit polyclonal anti-CD40 antiserum that blots were probed with.</text>
                    <arg n="0">rabbit polyclonal anti-CD40 antiserum</arg>
                    <arg n="1">C-terminus of CD40 at a 1:500 dilution</arg>
                </example>
                <example src="EGRAM" no="38">
                    <text>The NarL protein also bound to these 7-2-7 sites but, unlike NarP, also recognized heptamers in other arrangements.</text>
                    <arg n="0">The NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="EGRAM" no="39">
                    <text>The NarL protein has also bound to these 7-2-7 sites but, unlike NarP, has also recognized heptamers in other arrangements.</text>
                    <arg n="0">The NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="EGRAM" no="40">
                    <text>The NarL protein will binds to these 7-2-7 sites but, unlike NarP, will also recognize heptamers in other arrangements.</text>
                    <arg n="0">The NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="EGRAM" no="41">
                    <text>The STAT1 N-terminus are recognized by A monoclonal antibody purchasing from Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">A monoclonal antibody</arg>
                    <arg n="1">the STAT1 N-terminus</arg>
                </example>
                <example src="EGRAM" no="42">
                    <text>The STAT1 N-terminus were recognized by A monoclonal antibody purchasing from Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">A monoclonal antibody</arg>
                    <arg n="1">the STAT1 N-terminus</arg>
                </example>
                <example src="EGRAM" no="43">
                    <text>The eukaryotic upstream binding factor (UBF), has recognized the ribosomal RNA gene promoter and activated transcription mediated by RNA polymerase I through cooperative interactions with the species-specific factor, SL1.</text>
                    <arg n="0">The eukaryotic upstream binding factor (UBF)</arg>
                    <arg n="1">The ribosomal RNA gene promoter</arg>
                </example>
                <example src="EGRAM" no="44">
                    <text>The eukaryotic upstream binding factor (UBF), recognized the ribosomal RNA gene promoter and activated transcription mediated by RNA polymerase I through cooperative interactions with the species-specific factor, SL1.</text>
                    <arg n="0">The eukaryotic upstream binding factor (UBF)</arg>
                    <arg n="1">The ribosomal RNA gene promoter</arg>
                </example>
                <example src="EGRAM" no="45">
                    <text>The eukaryotic upstream binding factor (UBF), will recognize the ribosomal RNA gene promoter and activate transcription mediated by RNA polymerase I through cooperative interactions with the species-specific factor, SL1.</text>
                    <arg n="0">The eukaryotic upstream binding factor (UBF)</arg>
                    <arg n="1">The ribosomal RNA gene promoter</arg>
                </example>
                <example src="EGRAM" no="46">
                    <text>The lower form of Stat3, Stat3Beta, cannot be recognized in the immunoprecipitaiton with anti-Stat3 pAb as it is raised against a C-terminal region of Stat3 that is missing in Stat3Beta.</text>
                    <arg n="0">anti-Stat3 pAb</arg>
                    <arg n="1">The lower form of Stat3, Stat3Beta</arg>
                    <arg n="M-NEG">not</arg>
                </example>
                <example src="EGRAM" no="47">
                    <text>The lower form of Stat3, Stat3Beta, could not be recognized in the immunoprecipitaiton with anti-Stat3 pAb as it was raised against a C-terminal region of Stat3 that is missing in Stat3Beta.</text>
                    <arg n="0">anti-Stat3 pAb</arg>
                    <arg n="1">The lower form of Stat3, Stat3Beta</arg>
                    <arg n="M-NEG">not</arg>
                </example>
                <example src="EGRAM" no="48">
                    <text>The lower form of Stat3, Stat3Beta, has not been recognized in the immunoprecipitaiton with anti-Stat3 pAb as it was raised against a C-terminal region of Stat3 that is missing in Stat3Beta.</text>
                    <arg n="0">anti-Stat3 pAb</arg>
                    <arg n="1">The lower form of Stat3, Stat3Beta</arg>
                    <arg n="M-NEG">not</arg>
                </example>
                <example src="EGRAM" no="49">
                    <text>The lower form of Stat3, Stat3Beta, was not recognized in the immunoprecipitaiton with anti-Stat3 pAb as it was raised against a C-terminal region of Stat3 that is missing in Stat3Beta.</text>
                    <arg n="0">anti-Stat3 pAb</arg>
                    <arg n="1">The lower form of Stat3, Stat3Beta</arg>
                    <arg n="M-NEG">not</arg>
                </example>
                <example src="EGRAM" no="50">
                    <text>The lower form of Stat3, Stat3Beta, will not be recognized in the immunoprecipitaiton with anti-Stat3 pAb as it is raised against a C-terminal region of Stat3 that is missing in Stat3Beta.</text>
                    <arg n="0">anti-Stat3 pAb</arg>
                    <arg n="1">The lower form of Stat3, Stat3Beta</arg>
                    <arg n="M-NEG">not</arg>
                </example>
                <example src="EGRAM" no="51">
                    <text>The sequence(YPYDVPDYA) at a 1:500 dilution is recognized by a RAT monoclonal anti-HA antibody (Boehringer-Ingelheim) that blots were probed with.</text>
                    <arg n="0">a RAT monoclonal anti-HA antibody (Boehringer-Ingelheim)</arg>
                    <arg n="1">sequence(YPYDVPDYA) at a 1:500 dilution</arg>
                </example>
                <example src="EGRAM" no="52">
                    <text>The two forms of Stat3 (Stat3fm and Stat3sm) that are recognized by this antibody in PKR+/+MEFs are indicated.</text>
                    <arg n="0">this antibody in PKR+/+MEFs</arg>
                    <arg n="1">The two forms of Stat3 (Stat3fm and Stat3sm)</arg>
                </example>
                <example src="EGRAM" no="53">
                    <text>The two forms of Stat3 (Stat3fm and Stat3sm) that have been recognized by this antibody in PKR+/+MEFs are indicated.</text>
                    <arg n="0">this antibody in PKR+/+MEFs</arg>
                    <arg n="1">The two forms of Stat3 (Stat3fm and Stat3sm)</arg>
                </example>
                <example src="EGRAM" no="54">
                    <text>The two forms of Stat3 (Stat3fm and Stat3sm) that were recognized by this antibody in PKR+/+MEFs are indicated.</text>
                    <arg n="0">this antibody in PKR+/+MEFs</arg>
                    <arg n="1">The two forms of Stat3 (Stat3fm and Stat3sm)</arg>
                </example>
                <example src="EGRAM" no="55">
                    <text>The two forms of Stat3 (Stat3fm and Stat3sm) that will be recognized by this antibody in PKR+/+MEFs are indicated.</text>
                    <arg n="0">this antibody in PKR+/+MEFs</arg>
                    <arg n="1">The two forms of Stat3 (Stat3fm and Stat3sm)</arg>
                </example>
                <example src="EGRAM" no="56">
                    <text>The two forms of Stat3 (Stat3fm and Stat3sm) which can be recognized by this antibody in PKR+/+MEFs are indicated.</text>
                    <arg n="0">this antibody in PKR+/+MEFs</arg>
                    <arg n="1">The two forms of Stat3 (Stat3fm and Stat3sm)</arg>
                </example>
                <example src="EGRAM" no="57">
                    <text>The two forms of Stat3 (Stat3fm and Stat3sm) which were recognized by this antibody in PKR+/+MEFs are indicated.</text>
                    <arg n="0">this antibody in PKR+/+MEFs</arg>
                    <arg n="1">The two forms of Stat3 (Stat3fm and Stat3sm)</arg>
                </example>
                <example src="EGRAM" no="58">
                    <text>These bands can be detected with four different specific antibodies that recognize the different nonmuscle myosin heavy chain isoforms (A and B)</text>
                    <arg n="0">four different specific antibodies</arg>
                    <arg n="1">the different nonmuscle myosin heavy chain isoforms (A and B)</arg>
                </example>
                <example src="EGRAM" no="59">
                    <text>These bands can be detected with four different specific antibodies that recognized the different nonmuscle myosin heavy chain isoforms (A and B)</text>
                    <arg n="0">four different specific antibodies</arg>
                    <arg n="1">the different nonmuscle myosin heavy chain isoforms (A and B)</arg>
                </example>
                <example src="EGRAM" no="60">
                    <text>These bands can be detected with four different specific antibodies which have recognized the different nonmuscle myosin heavy chain isoforms (A and B)</text>
                    <arg n="0">four different specific antibodies</arg>
                    <arg n="1">the different nonmuscle myosin heavy chain isoforms (A and B)</arg>
                </example>
                <example src="EGRAM" no="61">
                    <text>These bands can be detected with four different specific antibodies which recognize the different nonmuscle myosin heavy chain isoforms (A and B)</text>
                    <arg n="0">four different specific antibodies</arg>
                    <arg n="1">the different nonmuscle myosin heavy chain isoforms (A and B)</arg>
                </example>
                <example src="EGRAM" no="62">
                    <text>These mutations, identified by standard methods of reverse transcription, PCR,dideoxy-chain termination, and cycle sequencing, alter highly conserved sequences at intron/exon boundaries and cause the RNA-splicing apparatus not to properly recognize the normal splice junction.</text>
                    <arg n="0">the RNA-splicing apparatus</arg>
                    <arg n="1">the normal splice junction</arg>
                </example>
                <example src="EGRAM" no="63">
                    <text>These mutations, identified by standard methods of reverse transcription, PCR,dideoxy-chain termination, and cycle sequencing, alter highly conserved sequences at intron/exon boundaries and cause the normal splice junction not to be properly recognized by the RNA-splicing apparatus.</text>
                    <arg n="0">the RNA-splicing apparatus</arg>
                    <arg n="1">the normal splice junction</arg>
                </example>
                <example src="EGRAM" no="64">
                    <text>These mutations, identified by standard methods of reverse transcription, PCR,dideoxy-chain termination, and cycle sequencing, alter highly conserved sequences at intron/exon boundaries and make the RNA-splicing apparatus not to recognized the normal splice junction properly.</text>
                    <arg n="0">the RNA-splicing apparatus</arg>
                    <arg n="1">the normal splice junction</arg>
                </example>
                <example src="EGRAM" no="65">
                    <text>These mutations, identified by standard methods of reverse transcription, PCR,dideoxy-chain termination, and cycle sequencing, alter highly conserved sequences at intron/exon boundaries and prevent the normal splice junction from being properly recognized by the RNA-splicing apparatus.</text>
                    <arg n="0">the RNA-splicing apparatus</arg>
                    <arg n="1">the normal splice junction</arg>
                </example>
                <example src="EGRAM" no="66">
                    <text>To define the subcellular location of HVDAC isoforms, HVDAC genes were modified so that the encoded proteins contain COOH-terminal epitopes which are recognized by either of two monoclonal antibodies.</text>
                    <arg n="0">either of two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="EGRAM" no="67">
                    <text>To define the subcellular location of HVDAC isoforms, HVDAC genes were modified so that the encoded proteins contain COOH-terminal epitopes which can be recognized by either of two monoclonal antibodies.</text>
                    <arg n="0">either of two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="EGRAM" no="68">
                    <text>To define the subcellular location of HVDAC isoforms, HVDAC genes were modified so that the encoded proteins contain COOH-terminal epitopes which have been recognized by either of two monoclonal antibodies.</text>
                    <arg n="0">either of two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="EGRAM" no="69">
                    <text>To define the subcellular location of HVDAC isoforms, HVDAC genes were modified so that the encoded proteins contain COOH-terminal epitopes which were recognized by either of two monoclonal antibodies.</text>
                    <arg n="0">either of two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="EGRAM" no="70">
                    <text>We show that the cAMP-CRP activator complex has recognized two sites in tsx-p2 that are separated by 33 bp : a high-affinity site (CRP-1) overlaps the-35 region, and a low-affinity site (CRP-2) is centered around position-74 bp.</text>
                    <arg n="0">the cAMP-CRP activator complex</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="EGRAM" no="71">
                    <text>We show that the cAMP-CRP activator complex recognized two sites in tsx-p2 that are separated by 33 bp : a high-affinity site (CRP-1) overlaps the-35 region, and a low-affinity site (CRP-2) is centered around position-74 bp.</text>
                    <arg n="0">the cAMP-CRP activator complex</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="EGRAM" no="72">
                    <text>We show that the cAMP-CRP activator complex will recognize two sites in tsx-p2 that are separated by 33 bp : a high-affinity site (CRP-1) overlaps the-35 region, and a low-affinity site (CRP-2) is centered around position-74 bp.</text>
                    <arg n="0">the cAMP-CRP activator complex</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="EGRAM" no="73">
                    <text>the ribosomal RNA gene promoter is recognized by The eukaryotic upstream binding factor (UBF).</text>
                    <arg n="0">The eukaryotic upstream binding factor (UBF)</arg>
                    <arg n="1">The ribosomal RNA gene promoter</arg>
                </example>
                <example src="EGRAM" no="74">
                    <text>the ribosomal RNA gene promoter was recognized by The eukaryotic upstream binding factor (UBF).</text>
                    <arg n="0">The eukaryotic upstream binding factor (UBF)</arg>
                    <arg n="1">The ribosomal RNA gene promoter</arg>
                </example>
                <example src="EGRAM" no="75">
                    <text>two sites in tsx-p2 are recognized by the cAMP-CRP activator complex.</text>
                    <arg n="0">the cAMP-CRP activator complex</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="EGRAM" no="76">
                    <text>two sites in tsx-p2 were recognized by the cAMP-CRP activator complex.</text>
                    <arg n="0">the cAMP-CRP activator complex</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
            </roleset>
        </predicate>
    </framesest>
</PASBIO>
